S Loi

Summary

Affiliation: Institut Jules Bordet
Country: Belgium

Publications

  1. pmc Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    BMC Med Genomics 2:37. 2009
  2. pmc Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection
    Carmen Criscitiello
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels
    Onco Targets Ther 4:1-11. 2011
  3. pmc PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer
    Sherene Loi
    Breast Cancer Translational Research Laboratory, Jules Bordet Institute, Brussels, Belgium
    PLoS ONE 8:e53292. 2013
  4. doi Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
    Sherene Loi
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Blvd de Waterloo, 125, 1000 Brussels, Belgium
    J Clin Oncol 31:860-7. 2013
  5. pmc Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context
    Gad Abraham
    Department of Computer Science and Software Engineering, The University of Melbourne, Parkville 3010, Vic, Australia
    BMC Bioinformatics 11:277. 2010
  6. doi HER2-overexpressing breast cancer: time for the cure with less chemotherapy?
    Sherene Loi
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, l Université Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 23:547-58. 2011
  7. pmc PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, East Melbourne 3002, Australia
    Proc Natl Acad Sci U S A 107:10208-13. 2010
  8. doi Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
    Eur J Cancer 44:2813-8. 2008
  9. ncbi Towards evidence-based use of serum tumour marker requests: an audit of use in a tertiary hospital
    S Loi
    Department of Medical Oncology and Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Intern Med J 34:545-50. 2004
  10. ncbi Castleman's disease and HIV infection in Australia
    S Loi
    Department of Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A becket Street, East Melbourne, Victoria 8006, Australia
    HIV Med 5:157-62. 2004

Collaborators

Detail Information

Publications19

  1. pmc Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    BMC Med Genomics 2:37. 2009
    ..When treated with adjuvant tamoxifen, those ER+ BCs that are lowly proliferative have a good prognosis (luminal-A subtype), however the clinical outcome of those that are highly proliferative is poor (luminal-B subtype)...
  2. pmc Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection
    Carmen Criscitiello
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels
    Onco Targets Ther 4:1-11. 2011
    ..A combination of gene expression and genetic aberration markers may be most useful in discerning a population that is still appropriate for adjuvant tamoxifen treatment...
  3. pmc PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer
    Sherene Loi
    Breast Cancer Translational Research Laboratory, Jules Bordet Institute, Brussels, Belgium
    PLoS ONE 8:e53292. 2013
    ..Further evaluation of the PIK3CA-GS as a predictive biomarker is warranted as it may facilitate better selection of responsive patient populations for mTOR inhibition in combination with letrozole...
  4. doi Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
    Sherene Loi
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Blvd de Waterloo, 125, 1000 Brussels, Belgium
    J Clin Oncol 31:860-7. 2013
    ..We hypothesized that increased lymphocytic infiltration would be associated with good prognosis and benefit from immunogenic CT-in this case, anthracycline-only CT-in selected BC subtypes...
  5. pmc Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context
    Gad Abraham
    Department of Computer Science and Software Engineering, The University of Melbourne, Parkville 3010, Vic, Australia
    BMC Bioinformatics 11:277. 2010
    ....
  6. doi HER2-overexpressing breast cancer: time for the cure with less chemotherapy?
    Sherene Loi
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, l Université Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 23:547-58. 2011
    ..We review these findings and reflect on how they may influence the next generation of clinical trials in this breast cancer subtype...
  7. pmc PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, East Melbourne 3002, Australia
    Proc Natl Acad Sci U S A 107:10208-13. 2010
    ..In ER+ BC cell lines, PIK3CA mutations were also associated with sensitivity to tamoxifen. These findings could have important implications for the treatment of PIK3CA-mutant BCs and the development of PI3K/mTOR inhibitors...
  8. doi Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
    Eur J Cancer 44:2813-8. 2008
    ....
  9. ncbi Towards evidence-based use of serum tumour marker requests: an audit of use in a tertiary hospital
    S Loi
    Department of Medical Oncology and Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Intern Med J 34:545-50. 2004
    ..Serum tumour markers (TM) are often measured in hospital patients. The reasons for their use and their benefits with regards to earlier cancer diagnosis and patient management are not known...
  10. ncbi Castleman's disease and HIV infection in Australia
    S Loi
    Department of Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A becket Street, East Melbourne, Victoria 8006, Australia
    HIV Med 5:157-62. 2004
    ..To describe, retrospectively, the Australian experience of multi-centric Castleman's disease (MCD) in the setting of HIV infection, specifically with the advent of HAART, and newer chemotherapeutic agents...
  11. ncbi Elucidating the biological basis of prognosis in young women with early breast cancer (BC) using gene expression profiling
    H A Azim
    Jules Bordet Institute, Brussels, Belgium Department of Medical Oncology, Princess Margaret and University of Toronto, Toronto, ON, Canada Dana Farber Cancer Institute, Boston, MA
    J Clin Oncol 29:10603. 2011
    ..Whether the performance of prognostic gene expression signatures (GS) varies by BC subtype across age groups is unknown...
  12. ncbi Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers
    S Loi
    Institut Jules Bordet, Brussels, Belgium M D Anderson Cancer Center, Houston, TX Institute for Cancer Research and Treatment, Torino, Italy Guy s Hospital, London, United Kingdom Peter MacCallum Cancer Center, Melbourne, Australia
    J Clin Oncol 27:533. 2009
    ..Our aim was to characterize the molecular and clinical outcome effects of PIK3CA mutations in breast cancer (BC)...
  13. ncbi Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxoru
    S Loi
    Jules Bordet Institute, Brussels, Belgium Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium IDDI, Louvain la Neuve, Belgium Institut Jules Bordet, Brussels, Belgium Breast European Adjuvant Studies Team, Jules Bordet Institute, Brussels, Belgium IBCSG Central Pathology Office, Milan, Italy Australian New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle, Australia Irish Clinical Oncology Research Group and Molecular Therapeutics for Cancer, Dublin, Ireland Swedish Oncology Group, Stockholdm, Sweden Clinica Las Condes, Santiago, Chile Department of Oncology, Rigshospitalet, Copenhagen, Denmark Grupo Espanol de Investigacion en Cancer de Mama, Madrid, Spain Medical University of Vienna, Vienna, Austria Division of Pathology, European Institute of Oncology, Milan, Italy Sandro Pitigliani Medical Oncology Unit, Prato, Italy
    J Clin Oncol 29:556. 2011
    ..We hypothesized that TILs would be associated with prognosis and would predict increased benefit from A-based over A-T CT regimens in the triple negative (TN) and HER2+BC...
  14. doi Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers
    D Fumagalli
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Free University of Bruxelles, Brussels, Belgium
    Ann Oncol 27:1860-6. 2016
    ..The molecular landscape of ER+ relapsed disease is not well characterized. In this study, we aimed to describe the genomic evolution between primary (P) and matched metastatic (M) ER+ BCs after failure of adjuvant therapy...
  15. doi The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
    R Salgado
    Breast Cancer Translational Research Laboratory Breast International Group, Institut Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp, Belgium
    Ann Oncol 26:259-71. 2015
    ..TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC...
  16. doi Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
    S Loi
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Ann Oncol 25:1544-50. 2014
    ..In this study, we aimed to validate these findings and also investigate associations with trastuzumab benefit in HER2-overexpressing disease (HER2+)...
  17. doi Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement
    H A Azim
    Breast Cancer Translational Research Laboratory BCTL, J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Ann Oncol 24:647-54. 2013
    ..We critically evaluated the available evidence on genomic tests in breast cancer to define their prognostic ability and likelihood to determine treatment benefit...
  18. doi Pertuzumab: new hope for patients with HER2-positive breast cancer
    M Capelan
    Department of Medicine, Institute Jules Bordet, l Université Libre de Bruxelles, Brussels, Belgium
    Ann Oncol 24:273-82. 2013
    ..Pertuzumab is a new anti-HER2 humanized monoclonal antibody that prevents the formation of HER2 dimers...
  19. pmc Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial
    S Loi
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, A Beckett Street, Melbourne, Victoria 8006, Australia
    Br J Cancer 92:655-61. 2005
    ..For future trials, oxaliplatin 85 mg m(-2) and 5-FU 200 mg m(-2) day(-1) continuous infusion 96 h week(-1) is the recommended dose when combined with 50.4 Gy of pelvic radiotherapy...